- Home
- TLSI vs GECC Comparison
TLSI vs GECC Comparison
Compare TLSI & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- GECC
- Stock Information
- Founded
- TLSI 2010
- GECC 2016
- Country
- TLSI United States
- GECC United States
- Employees
- TLSI N/A
- GECC N/A
- Industry
- TLSI Medical Specialities
- GECC Finance: Consumer Services
- Sector
- TLSI Health Care
- GECC Finance
- Exchange
- TLSI Nasdaq
- GECC Nasdaq
- Market Cap
- TLSI 150.3M
- GECC 121.9M
- IPO Year
- TLSI N/A
- GECC N/A
- Fundamental
- Price
- TLSI $4.93
- GECC $10.69
- Analyst Decision
- TLSI Strong Buy
- GECC
- Analyst Count
- TLSI 6
- GECC 0
- Target Price
- TLSI $11.75
- GECC N/A
- AVG Volume (30 Days)
- TLSI 33.1K
- GECC 29.5K
- Earning Date
- TLSI 11-14-2024
- GECC 02-27-2025
- Dividend Yield
- TLSI N/A
- GECC 13.56%
- EPS Growth
- TLSI N/A
- GECC N/A
- EPS
- TLSI N/A
- GECC 0.65
- Revenue
- TLSI $26,891,000.00
- GECC $39,468,000.00
- Revenue This Year
- TLSI $60.96
- GECC $17.68
- Revenue Next Year
- TLSI $53.65
- GECC $4.96
- P/E Ratio
- TLSI N/A
- GECC $16.43
- Revenue Growth
- TLSI 67.90
- GECC 16.86
- 52 Week Low
- TLSI $3.50
- GECC $9.55
- 52 Week High
- TLSI $10.42
- GECC $11.31
- Technical
- Relative Strength Index (RSI)
- TLSI 56.22
- GECC 56.34
- Support Level
- TLSI $4.53
- GECC $10.02
- Resistance Level
- TLSI $4.92
- GECC $10.80
- Average True Range (ATR)
- TLSI 0.29
- GECC 0.33
- MACD
- TLSI -0.02
- GECC 0.01
- Stochastic Oscillator
- TLSI 50.63
- GECC 62.96
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. The company seeks to generate current income and capital appreciation through debt and equity investments, including investments in specialty finance businesses. It invests in senior secured and senior unsecured debt instruments, as well as in junior loans and mezzanine debt of middle-market companies and small businesses. The company generates revenue from interest on the debt investments that it holds.